DOWNLOAD THIS SLIDE KIT

• Pilot, open-label retrospective study
• 28 adults on salvage therapy with enfuvirtide-based regimen and HIV-1 RNA < 50 c/mL
• Switch of enfuvirtide to RAL 400 mg bid, the remainder of the salvage regimen being unchanged. At the time of the switch:
  • ENF had been administered for a median of 25 months
  • Salvage regimen: 1 PI/r, N = 27, 1 NNRTI, N = 6
• Follow-up of 6 months available for 27/28 patients
  • 26 maintained HIV-1 RNA < 50 c/mL
  • 1 single blip at 56 c/mL at W24
  • No significant changes in the CD4 counts
  • ENF-related injection site reactions resolved in all patients
  • RAL was well tolerated